USOTCUnited States Olympic Training Center
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Starpharma Holdings Limited (USOTC: SPHRY; ASX: SPL) leads the world in the application of nanotechnology to pharmaceuticals.
Cannabis beverages company Puration Inc (USOTC:PURA) said on Thursday that Nouveau Life Pharmaceuticals Inc (USOTC:NOUV) declared a stock dividend in the ratio of one to five of NOUV common stock.
(USOTC :ALYI ), a company focused on offering varied, environmentally sustainable, energy storage solutions for targeted markets, including consumer electric vehicles and military applications, has announced an order for twenty-five of its ReVolt Electric Motorcycles.
Biotechnology company CSL Limited (ASX:CSL) (USOTC:CSLLY) stated on Tuesday that it plans to expedite the development of clazakizumab (an anti-IL6 MAB, formerly ALD518) as a therapeutic option for solid organ transplant rejection in a strategic collaboration and purchase option agreement with Vitaeris Inc.
NEW YORK, NY., October 27, 2015 -- Mesoblast Limited (USOTC:MBLTY) was awarded a U.S.
NEW YORK, N.Y., September 18, 2015 -- Mesoblast Limited (USOTC:MBLTY) said that its licensee JCR Pharmaceuticals Co.
The trial used Mesenchymal Precursor Cells (MPCs) provided by Mesoblast Limited (USOTC: MBLTY).
(USOTC: KALY) has entered the cannabis pharmaceuticals market with the acquisition of Rhode Island, US-based biotech company NCM Biotech, a developer and owner of a patented cannabis extraction process, the company said.
(USOTC: ALYI) has received a contract for 100 units of its ReVolt Electric Motorcycles.
MELBOURNE, Australia, June 8, 2015--Mesoblast Limited (USOTC: MBLTY) announced that results from the company's Phase 2 trial in patients
MELBOURNE, Australia, June 8, 2015--Mesoblast Limited (USOTC: MBLTY) announced encouraging results from a Phase 2 trial in patients with diabetic nephropathy.
31 January 2011 - UK-based biopharmaceutical company Antisoma plc (LSE: ASM; USOTC: ATSMY) announced today that the ACCEDE Phase III trial of AS1413 (amonafide) in secondary acute myeloid leukemia (secondary AML) did not meet its primary endpoint.